This article explores Leash Bio, a startup focused on machine learning for drug discovery. It highlights the challenges of ensuring model accuracy and the potential for unintentional bias in research, while showcasing Leash Bio's commitment to ethical practices in a complex field.

TxGemma is a new collection of open models designed to enhance therapeutic development by utilizing large language models. Fine-tuned from Google DeepMind's Gemma, these models can predict therapeutic properties and assist in drug discovery, while also offering conversational capabilities for deeper insights. Researchers can further customize TxGemma using their own data, potentially accelerating the development process for new therapies.